Trends in blood gene expression in non-small cell lung cancer patients treated with bevacizumab.

e22002 Background: Bevacizumab (BV) has shown increased overall response rate and survival in patients (Pt) with non-small cell lung cancer (NSCLC). No biomarkers have been described predictors of response in these Pt. The aim of this study is to investigate the usefulness of gene expression profiles of peripheral blood monocytes from patients with NSCLC before and after chemotherapy plus BV. Methods: A prospective study of blood samples from Stage IV NSCLC Pt treated with BV plus chemotherapy in our institution between 2009 and 2010 was performed. Plasma samples were collected before cycle 1 and after completion of cycle 2 (week 7). Clinical and radiological outcomes were recorded. The TaqMan Human Angiogenesis Array was used for analysis (micro fluidic card). This array contains 96 target involved in human angiogenesis and lymphangiogenesis. Amplifications were carried out on the AB 7900HT RT-PCR system, and relative gene expression values were calculated by the ΔΔCt method. Results: We present prelimin...